Should You Buy Sangamo Therapeutics Inc (SGMO) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
0.510
1 Day change
40.95%
52 Week Range
1.400
Analysis Updated At
2026/01/26
Sangamo Therapeutics Inc (SGMO) is not a strong buy for a beginner investor with a long-term focus at this time. The company's financial performance is significantly deteriorating, technical indicators are bearish, and there are no strong positive catalysts or favorable trading signals to justify an immediate investment. It is better to wait for clearer signs of recovery or positive developments.
Technical Analysis
The technical indicators are bearish. The MACD is negatively expanding below 0, RSI is at 33.256 (neutral but close to oversold), and the moving averages indicate a downward trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 0.376, but there is no clear reversal signal.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Options data shows a low put-call ratio, indicating limited bearish sentiment, but the implied volatility is high (105.94%) with a low IV percentile (2.4%), suggesting the stock is not attracting significant speculative interest.
Technical Summary
Sell
6
Buy
11
Positive Catalysts
The FDA reaffirmed an accelerated approval path for one of the company's treatments, and the cash runway has been extended into Q1 2026.
Neutral/Negative Catalysts
There are no recent insider or hedge fund trading trends, and no recent news or congress trading activity.
Financial Performance
The company's Q3 2025 financials are weak: Revenue dropped by -98.82% YoY to $581,000, net income fell by -472.19% YoY to -$34.93M, and EPS decreased by -375.00% YoY to -0.11. Gross margin remained flat at 100%.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Barclays downgraded the stock to Equal Weight from Overweight and reduced the price target to $1 from $5, citing a lack of clarity on a Fabry deal despite the FDA's reaffirmation of an accelerated approval path.
Wall Street analysts forecast SGMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMO is 3.75 USD with a low forecast of 1 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast SGMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMO is 3.75 USD with a low forecast of 1 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
3 Hold
0 Sell
Hold
Current: 0.364
Low
1
Averages
3.75
High
10
Current: 0.364
Low
1
Averages
3.75
High
10
Barclays
Overweight -> Equal Weight
downgrade
$5 -> $1
AI Analysis
2025-11-07
Reason
Barclays
Price Target
$5 -> $1
AI Analysis
2025-11-07
downgrade
Overweight -> Equal Weight
Reason
Barclays downgraded Sangamo to Equal Weight from Overweight with a price target of $1, down from $5. The company's Q3 report highlighted the FDA's reaffirmation of an accelerated approval path using eGFR slope as the endpoint and its cash runway has been extended into Q1 of 2026, the analyst tells investors in a research note. Barclays steps to the sidelines pending further clarity on a Fabry deal.
Barclays
Overweight
downgrade
$9 -> $5
2025-05-14
Reason
Barclays
Price Target
$9 -> $5
2025-05-14
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Sangamo to $5 from $9 and keeps an Overweight rating on the shares. The company's Q1 call provided additional color on cash runway extended into late Q3 by the capital raise, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SGMO
